Dr Federica BegalliLecturer in EndocrinologyCentre: EndocrinologyEmail: f.begalli@qmul.ac.ukProfileResearchPublicationsSponsorsCollaboratorsTeachingDisclosuresProfileORCID iD: 0000-0002-7478-0252LinkedIn Federica obtained her BSc in Biotechnology and her MSc cum laude in Medical, Molecular and Cellular Biotechnology from La Sapienza University of Rome. She obtained her PhD in Biomedical Technologies in Clinical Medicine from La Sapienza University of Rome as part of a joint project with Imperial College London. Federica held her first post-doctoral position at Imperial College London, where she secured funding for her own project with Bloodwise and she started teaching in the MSc Program in Molecular Medicine. During her PhD and her first post-doc, Federica developed a passion for translational science. Following this led her to a second post-doc in Marta Korbonits’ laboratory at Queen Mary University of London, where she started a collaboration with ONO Pharmaceutical and secured two rounds of funding for their collaborative projects. At QMUL, Federica also started lecturing and teaching PBLs as part of the BSc in Pharmacology and Innovative Therapeutics, as well as the MBBS, and she obtained the Fellowship of Higher Education Academy in 2020. Since January 2023, Federica is a Lecturer in Endocrinology and Education Lead for the Centre for Endocrinology. She co-leads two modules in Endocrine Physiology and Biochemistry. Federica is member of the British Society for Endocrinology, the European Society of Endocrinology, European Neuroendocrine Association.ResearchFederica’s main research interest is to unveil the molecular mechanisms behind tumour development and progression and use her findings in clinical applications. Her research focuses on Non-Functioning Pituitary Neuroendocrine Tumours, where she is developing novel biomarkers as well as therapeutic strategies. She works closely with clinicians and pharmaceutical companies to achieve these goals.Publications Begalli F, Komagata T, Suleyman O et al. (publicationYear). Cabergoline treatment in human primary non-functioning pituitary adenomas. nameOfConference DOI: 10.1530/endoabs.77.p212 QMRO: https://uat2-qmro.qmul.ac.uk/xmlui/handle/123456789/75749 Capece D, Verzella D, Begalli F et al. (2021). Extracellular Flux Analysis to Investigate the Impact of NF-κB on Mitochondrial RespirationMitochondrial respiration in Colorectal Carcinoma (CRC). nameOfConference DOI: 10.1007/978-1-0716-1669-7_18 QMRO: qmroHref Capece D, D'Andrea D, Begalli F et al. (2021). Enhanced triacylglycerol catabolism by Carboxylesterase 1 promotes aggressive colorectal carcinoma. nameOfConference DOI: 10.1172/jci137845 QMRO: qmroHref Rajpoot S, Bennett J, Franzoso G et al. (2020). Reprogramming immunosuppressive tumour-associated dendritic cells with GADD45β inhibitors. nameOfConference DOI: 10.7861/clinmed.20-2-s116 QMRO: qmroHref Mistry A, Solomou A, Vignola ML et al. (publicationYear). Investigating the role of AIP in pituitary tumourigenesis. nameOfConference DOI: 10.1530/endoabs.65.oc2.2 QMRO: qmroHref Bollington M, Mistry A, Solomou A et al. (publicationYear). Transcriptomic analyses reveal deregulation of focal adhesion pathway in Aip KO mice and AIP mutation positive human tumours. nameOfConference DOI: 10.1530/endoabs.65.op6.2 QMRO: qmroHref Tornatore L, Capece D, D'Andrea D et al. (2019). Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. nameOfConference DOI: 10.1016/j.toxrep.2019.04.006 QMRO: qmroHref Tornatore L, Capece D, D'Andrea D et al. (2019). Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma. nameOfConference DOI: 10.1111/bjh.15569 QMRO: qmroHref Capece D, D’Andrea D, Verzella D et al. (2018). Turning an old GADDget into a troublemaker. nameOfConference DOI: 10.1038/s41418-018-0087-6 QMRO: qmroHref Verzella D, Bennett J, Fischietti M et al. (2018). GADD45β Loss Ablates Innate Immunosuppression in Cancer. nameOfConference DOI: 10.1158/0008-5472.can-17-1833 QMRO: qmroHref Bennett J, Capece D, Begalli F et al. (2018). NF-κB in the crosshairs: Rethinking an old riddle. nameOfConference DOI: 10.1016/j.biocel.2017.12.020 QMRO: qmroHref Bennett J, Capece D, Begalli F et al. (2018). NF-κB in the crosshairs: Rethinking an old riddle. nameOfConference DOI: 10.1016/j.biocel.2017.12.020 QMRO: qmroHref Begalli F, Bennett J, Capece D et al. (publicationYear). Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. nameOfConference DOI: 10.3390/biomedicines5030050 QMRO: qmroHref Miele E, Po A, Begalli F et al. (2017). β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. nameOfConference DOI: 10.1186/s12885-017-3477-0 QMRO: qmroHref Po A, Begalli F, Abballe L et al. (2017). β‐Arrestin1/miR‐326 Transcription Unit Is Epigenetically Regulated in Neural Stem Cells Where It Controls Stemness and Growth Arrest. nameOfConference DOI: 10.1155/2017/5274171 QMRO: qmroHref Miele E, Buttarelli FR, Arcella A et al. (2014). High-throughput microRNA profiling of pediatric high-grade gliomas. nameOfConference DOI: 10.1093/neuonc/not215 QMRO: qmroHref Garg N, Po A, Miele E et al. (2013). microRNA‐17‐92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1. nameOfConference DOI: 10.1038/emboj.2013.214 QMRO: qmroHref Leonard A, Wolff J, Sengupta R et al. (2012). HIGH GRADE GLIOMAS. nameOfConference DOI: 10.1093/neuonc/nos102 QMRO: qmroHref Miele E, Buttarelli F, Arcella A et al. (2012). DIFFERENTIAL PROFILES OF MicroRNAS IN PEDIATRIC AND ADULT HIGH GRADE GLIOMAS. nameOfConference DOI: doi QMRO: qmroHref Miele E, Ferretti E, Po A et al. (2011). Abstract 3396: Neural stem cells, cancer stem cells and microRNAs: The medulloblastoma paradigm. nameOfConference DOI: 10.1158/1538-7445.am2011-3396 QMRO: qmroHref Sponsors ONO Pharmaceutical Co., Ltd. CollaboratorsInternal Prof Márta Korbonits Dr Carles Gaston-Massuet Dr Jack Williams Giulia Mastroianni External Prof Peter McCormick Mr Pinaki Dutta Dr Ashutosh Rai TeachingFederica is Education Lead for the Department for Endocrinology. She co-leads two modules in “Endocrinology Physiology and Biochemistry”, BMD311 in London and SNU303 in Nanchang, China. Furthermore, she contributes to other teaching modules in the School of Medicine and Dentistry, in the BSc in Pharmacology and Innovative Therapeutics, and in the Nanchang Joint Programme. Federica is a Fellow of the Higher Education Academy since 2020. She has been supervising and mentoring students as well as research staff since 2011, for a total of: 6 BSc students (primary supervisor) 1 BMedSci student 3 MSc students 1 MRes student 4 PhD students 1 Laboratory Technician 2 Post-doc Researchers Disclosures In 2021 – 2023 Dr Federica Begalli has received a project grant funding from ONO Pharmaceutical Co., Ltd. In 2020 – 2021 Dr Federica Begalli has received a project grant funding from ONO Pharmaceutical Co., Ltd. Back to top